Doctiplus - We are allways here!

Mn-Sn: 8am to 9pm

Cancer & Oncology — Weekly Report — October 5, 2026

Home/Health Insights/Cancer & Oncology — October 5 – October 12, 2026
Vol. 7 · No. 47
DoctiPlus Care · Weekly Brief on Cancer & Oncology
Updated Monday · November 16, 2026
Cancer & Oncology · October 5 – October 12, 2026

Cancer & Oncology
Weekly Report

This week's data 159 new clinical trials registered across 10 countries, with 18,782 trials actively recruiting patients worldwide.
Week of October 5 – October 12, 2026
  • 159 new clinical trials registered across 10 countries.
  • 18,782 trials actively recruiting patients worldwide.
  • Notable trial: Emulation of the MAVERICC Trial Using Specialty Oncology Electronic Health Records Databases (9978 patients).
  • 2,377 new research papers published.
  • Drug safety: Most reported effect across tracked medications (pembrolizumab, nivolumab, trastuzumab, rituximab, paclitaxel) was Off Label Use.
  • No active drug recalls for tracked medications this week.

The week in numbers

Figures · October 5 – October 12, 2026
New Trials This Week
159.
registered Oct 5–Oct 12
Recruiting Now
18,782
active trials seeking patients
Countries
10
with active trials this week
Papers Published
2,377
new studies this week
Phase 3 Trials
3
late-stage trials this week
Fig. 01

Trials by country

Count · October 5 – October 12, 2026
China
25
United States
20
Not specified
12
Japan
12
France
5
Germany
4
Turkey (Türkiye)
2
Denmark
2
Iran
1
Greece
1
0 7 14 21 25
total
Fig. 02

Trials by phase

Distribution · October 5 – October 12, 2026

New clinical trials registered this week for Cancer & Oncology. Each trial links to its full record on ClinicalTrials.gov where you can find eligibility criteria, locations, and contact information.

§ 03

This week's new registrations

Click any header to sort

159 trials registered for Cancer & Oncology. Each links to its full record on ClinicalTrials.gov.

# Trial ↓ Phase ↕ Status ↕ Enrollment ↕ Country ↕
01 Islamic Spiritual Care Versus Psychological Support in Radiotherapy Cancer & Oncology · Dr Abdurrahman Yurtaslan Ankara Oncology Training and Research Hospital (NCT07861451) Other Completed 137 Turkey (Türkiye)
02 Biomarker Testing to Predict Radiation-Related Heart Disease in Lung Cancer Patients Cancer & Oncology · Duke University (NCT07869329) Other Not Yet Recruiting 50 United States
03 Emulation of the MAVERICC Trial Using Specialty Oncology Electronic Health Records Databases Cancer & Oncology · Brigham and Women's Hospital (NCT07861386) Other Active Not Recruiting 9,978 United States
04 Response-Guided Bladder Preservation With Trastuzumab Rezetecan, Adebrelimab, and Concurrent Bladder Radiotherapy in HER2-Expressing Muscle-Invasive Bladder Cancer Cancer & Oncology · Tongji Hospital (NCT07865611) Phase 2 Not Yet Recruiting 70 China
05 CT- Versus MRI-Based Planning for High-Dose-Rate Prostate Brachytherapy for Prostate Cancer Cancer & Oncology · Emory University (NCT07859722) Other Not Yet Recruiting 100 United States
06 Study of Vaping Use Among Adolescent and Young Adult Patients With Cancer Cancer & Oncology · Memorial Sloan Kettering Cancer Center (NCT07860801) Other Enrolling By Invitation 80 United States
07 Feasibility Study of a Sports-Inspired Onco-Coaching Progranm for Young Adults i Cancer Remission Cancer & Oncology · Institut Paoli-Calmettes (NCT07861971) Other Recruiting 19 France
08 GST101 in Participants With RAS-Mutant Advanced Solid Tumors Cancer & Oncology · Genuine Seed Therapeutics (Zhuhai) Co., Ltd. (NCT07868172) Phase 2 Not Yet Recruiting 172 China
09 Study to Assess the Efficacy and Safety of Rina-S Plus Standard of Care Compared to Standard of Care Maintenance Treatment After First-line (1L) Platinum-based Chemotherapy in Participants With Ovarian Cancer Cancer & Oncology · Genmab (NCT07859215) Phase 3 Not Yet Recruiting 602 N/A
10 Neoadjuvant Chemoradiotherapy Combined With QL1706 for MSS-Type Low-Rectal Cancer Cancer & Oncology · Changhai Hospital (NCT07866313) Phase 3 Recruiting 60 China
11 Design and Pilot Implementation of a Chatbot to Support Breast Cancer Screening Among Black Women Cancer & Oncology · University of Washington (NCT07858825) Other Not Yet Recruiting 873 N/A
12 Trastuzumab/Pertuzumab With Fulvestrant and Kurmoxilil in HR+/HER2+ Early Breast Cancer Cancer & Oncology · Hebei Medical University Fourth Hospital (NCT07857226) Phase 2 Not Yet Recruiting 31 N/A
13 A Study to Evaluate the Efficacy and Safety of Pemigatinib in Participants With Advanced/Metastatic or Surgically Unresectable Cholangiocarcinoma With FGFR2 Fusion or Rearrangements After at Least 1 Prior Line of Systemic Therapy Cancer & Oncology · Incyte Corporation (NCT07862998) Phase 2 Not Yet Recruiting 72 N/A
14 Trial of First-line Gemcitabine and Nab-paclitaxel With or Without L-glutamine in Advanced Pancreatic Cancer Cancer & Oncology · Jun Gong, MD (NCT07864571) Phase 2 Not Yet Recruiting 200 United States
15 Study Using a Drug-device Combination Product to Determine Safety, Tolerability and Antitumor Activity for Patients With Advanced, Non-small Cell Lung Cancer Cancer & Oncology · Nob Hill Therapeutics, Inc. (NCT07864584) Phase 2 Not Yet Recruiting 100 United States
16 Measurement of Ocular Microtremor With the iTremor Device in a Diverse US Cohort Cancer & Oncology · Head Diagnostics (NCT07858214) Other Enrolling By Invitation 120 United States
17 Benefits of Nutritional Supplement in Cancer Care Cancer & Oncology · The Hong Kong Polytechnic University (NCT07869290) Other Not Yet Recruiting 100 N/A
18 Phase 1 Trial of ACE723, A Dual-Payload Antibody Drug Conjugate, in Patients With Advanced HCC Who Have Failed or Progressed on Standard Systemic Therapy Containing ICIs Cancer & Oncology · Acepodia Biotech, Inc. (NCT07861425) Phase 1 Not Yet Recruiting 70 China
19 Gamified Virtual Reality Exercise for Suicidal Ideation in Older Adults Cancer & Oncology · Islamic Azad University, Sanandaj (NCT07862803) Other Completed 200 Iran
20 Neoadjuvant Chemotherapy Combined With Bispecific Antibody Versus Combined With Monoclonal Antibody in Locally Advanced NSCLC Cancer & Oncology · Shanghai Pulmonary Hospital, Shanghai, China (NCT07863999) Phase 3 Recruiting 290 China
21 Plant-derived Nutrients in the Prevention and Prognosis of Breast Cancer in Women. Cancer & Oncology · Keda Yu (NCT07868159) Other Active Not Recruiting 639 China
22 Physical Activity Education and Quality of Life Study in Breast Cancer Chemotherapy Patients Cancer & Oncology · International Hellenic University (NCT07864909) Other Active Not Recruiting 115 Greece
23 A Study of Secondary Immunodeficiencies in Adults With Blood Cancers in Kazakhstan Who Have a Weakened Immune System (K-SIDE Study) Cancer & Oncology · Takeda (NCT07868107) Other Not Yet Recruiting 200 Kazakhstan
24 Evaluation of the Efficacy and Acceptability of a Phytotherapy Combining Devil's Claw, Blackcurrant and Meadowsweet for the Management of Aromatase Inhibitor-induced Arthralgia in Patients Treated for Localized Breast Cancer in the Adjuvant Setting Cancer & Oncology · Hospices Civils de Lyon (NCT07859319) Phase 4 Not Yet Recruiting 105 France
25 Feasibility of Automatic, Laser-based Distance Control in Persons With Superficial Bladder Tumors Cancer & Oncology · Optheras AS (NCT07860398) Other Recruiting 25 Denmark
26 TMZ + RT + 5-ALA + LIDU SDT System for Newly Diagnosed Butterfly Glioma Cancer & Oncology · Alpheus Medical, Inc. (NCT07862647) Phase 1 Recruiting 30 United States
27 A Study to Investigate the Effect of Omeprazole and Cyclosporine on Velzatinib in Healthy Participants Cancer & Oncology · GlaxoSmithKline (NCT07862114) Phase 1 Not Yet Recruiting 36 N/A
28 Prevention of Bile Leakage After Liver Resection in Children Cancer & Oncology · Federal Research Institute of Pediatric Hematology, Oncology and Immunology (NCT07867522) Other Recruiting 12 Russia
29 Zolbetuximab and Other Cancer Treatments in People With Advanced Gastric or GEJ Cancer in Clinical Practice (RADIANCE) Cancer & Oncology · Astellas Pharma Europe Ltd. (NCT07858500) Other Not Yet Recruiting 1,000 Canada
30 Dermoscopic and Histopathological Patterns of Pigmented Skin Lesions Cancer & Oncology · Sohag University (NCT07863076) Other Recruiting 400 Egypt
31 Tissue Validation of Mammographic Breast Arterial Calcification in Mastectomy Specimens (SIDEMARA) Cancer & Oncology · Sehit Prof. Dr. Ilhan Varank Sancaktepe Training and Research Hospital (NCT07865884) Other Not Yet Recruiting 100 N/A
32 Paediatric Sarcoma, Hybrid Imaging & FAPI - Raising the Diagnostic Standard for Paediatric Sarcoma Patients, Combining Novel Radiotracer FAPI and Whole-body PET/MRI Cancer & Oncology · Copenhagen University Hospital, Rigshospitalet (NCT07861217) Phase 2 Not Yet Recruiting 40 Denmark
33 Metronomic Temozolomide With Dexbrompheniramine for Recurrent High-Grade Glioma/Glioblastoma Cancer & Oncology · University of Nebraska (NCT07859059) Phase 2 Not Yet Recruiting 41 United States
34 Management and Outcomes of Local Complications of Acute Pancreatitis and Postoperative Pancreatic Fistula Cancer & Oncology · Tokyo University (NCT07862088) Other Recruiting 5,000 Japan
35 Neoadjuvant Iparomlimab and Tuvonralimab With Nab-P-SOX in Locally Advanced Gastric or Gastroesophageal Junction Cancer Cancer & Oncology · Ruijin Hospital (NCT07867392) Phase 2 Recruiting 28 China
36 Sintilimab Combined With Chemoradiotherapy as Neoadjuvant Therapy for Locally Advanced Gastroesophageal Junction Cancer Cancer & Oncology · Anhui Medical University (NCT07859410) Other Not Yet Recruiting 50 China
37 Radial Shock Wave Treatment Alongside Decongestive Care for Arm Swelling After Breast Cancer Cancer & Oncology · Selcuk University (NCT07862296) Other Completed 21 Turkey (Türkiye)
38 Cervical Cancer Awareness Education to Aid Confidence and Screening upTake (ACT): A Pilot Randomised Control Trial Cancer & Oncology · Teesside University (NCT07863596) Other Not Yet Recruiting 76 N/A
39 Radiotherapy Target Volume Delineation in Locally Advanced Esophageal Cancer in the Immunotherapy Era Cancer & Oncology · Cancer Institute and Hospital, Chinese Academy of Medical Sciences (NCT07858630) Other Recruiting 500 China
40 Animal-Assisted Intervention for Children With Cancer and Their Siblings Cancer & Oncology · Azienda Ulss 2 Marca Trevigiana (NCT07861620) Other Completed 50 Italy
41 A Study to Evaluate the Effects of GDC-4198 in Combination With Letrozole, Fulvestrant, or Giredestrant in Participants With Locally Advanced or Metastatic Hormone Receptor-Positive, HER2-Negatve Breast Cancer Cancer & Oncology · Genentech, Inc. (NCT07867262) Phase 1 Not Yet Recruiting 165 N/A
42 A Study to Evaluate the Safety and Activity of GDC-7035 With Anti-Cancer Therapies in Participants With KRAS G12D-Mutated Unresectable Advanced or Metastatic Colorectal Cancer or Pancreatic Ductal Adenocarcinoma Cancer & Oncology · Genentech, Inc. (NCT07859085) Phase 1 Not Yet Recruiting 388 N/A
43 Stellate Ganglion Block and Dexmedetomidine for Postoperative Sleep in Women Undergoing Laparoscopic Gynecologic Surgery Cancer & Oncology · Catherin Zhang (NCT07860203) Other Recruiting 100 China
44 Emulation of the SUNLIGHT Trial Using Specialty Oncology Electronic Health Records Databases Cancer & Oncology · Brigham and Women's Hospital (NCT07861360) Other Active Not Recruiting 400 United States
45 Multi-peptide Vaccination and Bispecific PSMAxCD3 Antibody Treatment in Patients With Prostate Cancer Cancer & Oncology · University Hospital Tuebingen (NCT07860047) Phase 2 Recruiting 84 Germany
46 A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Efficacy of SYS6088 in Patients With Advanced/Metastatic Solid Tumors Cancer & Oncology · CSPC Megalith Biopharmaceutical Co.,Ltd. (NCT07857135) Phase 2 Not Yet Recruiting 140 N/A
47 Study of JMBI-001 in Patients With MYC-Positive Advanced Cancers Cancer & Oncology · Chengdu Anticancer Bioscience, Ltd. (NCT07864701) Phase 2 Not Yet Recruiting 150 N/A
48 De-EscaLaTion of Aromatase Inhibitor Therapy: A Randomized Phase II Study of De-escalated Letrozole in Hormone Receptor-Positive Early Breast Cancer Cancer & Oncology · Montefiore Medical Center (NCT07866430) Phase 2 Not Yet Recruiting 144 United States
49 Sarcoma Care Adherence and Survival in Strasbourg Cancer & Oncology · University Hospital, Strasbourg, France (NCT07864870) Other Recruiting 900 France
50 Surgery vs. Watch-and-Wait Strategy in Complete Responders for Hepatocellular Carcinoma Cancer & Oncology · West China Hospital (NCT07866612) Other Not Yet Recruiting 60 China
§ 04

Adverse event reports

FDA FAERS · 2025 data

Adverse drug event reports compiled from the FDA's FAERS database for medications commonly prescribed for Cancer & Oncology. These reports reflect what patients and healthcare providers have reported — they do not confirm a drug caused the effect.

Reports by drug

DrugTop effectCount
pembrolizumab Malignant Neoplasm Progression 1,762
nivolumab Off Label Use 819
trastuzumab Myelosuppression 707
rituximab Off Label Use 5,551
paclitaxel Myelosuppression 1,062

Recalls & safety notices

§ 05 · 0 items this week

FDA drug recall notices for medications related to Cancer & Oncology. If your medication is listed, contact your pharmacist or visit fda.gov/safety/recalls for guidance. No recall listed does not guarantee safety — always consult your healthcare provider.

No active drug recalls for tracked medications this period.

§ 06

Published research

2,377 papers

Recently published peer-reviewed studies related to Cancer & Oncology, sourced from PubMed and Semantic Scholar. Click any title to read the full paper, or expand the abstract for a quick summary.

# Study Journal Date Source
01 Fine-tuning the beam: Biomarker-guided radiation strategies in the evolving management of isocitrate dehydrogenase (IDH)-mutant glioma. Marciscano AE et al. 10.1093/neuonc/noag169
View abstract

Sequential chemoradiotherapy remains a standard treatment option for patients with isocitrate dehydrogenase (IDH)-mutant gliomas. The results of the phase III INDIGO trial have led to the recent regulatory approval of vorasidenib, a brain-penetrant IDH1 and IDH2 inhibitor, indicated for patients with IDH1- or IDH2-mutant WHO grade 2 astrocytoma or oligodendroglioma after biopsy or resection. While IDH inhibitors represent a significant advancement for patients with IDH-mutant glioma, there is substantial controversy regarding which patients are most likely to derive benefit from IDH inhibition and how this strategy can be optimally integrated into clinical practice. Specifically, whether IDH inhibitors should be used prior to, in conjunction with or potentially in lieu of radiation-based treatment strategies are fundamental questions for the neuro-oncology community. Additionally, whether IDH inhibitors can be extrapolated to higher-grade disease settings or utilized in higher-risk patient populations remains unknown. These open questions provide an opportunity for the field of radiation oncology to develop pragmatic biomarker-based approaches to guide patient selection, to monitor treatment response and to identify optimal treatment strategy and timing/sequencing of treatment. Several candidate biomarkers have emerged for IDH-mutant glioma with unique potential to be rationally integrated into radiation oncology workflows to personalize care.

Neuro-oncology 2026 Oct 10 PubMed
02 Reference frame for Adult Brainstem gliomas. Laigle-Donadey F et al. 10.1093/oncolo/oyag403
View abstract

Brainstem gliomas (BSG) are rare in adults (less than 2% of all gliomas) and generally have a better prognosis than pediatric BSG, although outcomes remain heterogeneous. Many other central nervous system (CNS) tumors, as well as nontumoral lesions, have been described as differential diagnoses and should be kept in mind. Each case should be examined by neurosurgeons from specialized centers to determine the most appropriate surgical approach among stereotactic biopsy, open biopsy, and tumor resection. Surgery may sometimes be performed in expert centers. The main objectives of tumor tissue sampling are to perform histomolecular analyses to confirm the diagnosis, determine the tumor subtype, and identify potential prognostic and theranostic biomarkers. Tissue preservation is essential to ensure that sufficient tumor material is available for further molecular analyses for diagnostic or therapeutic purposes. Results of ctDNA detection in CSF should only be considered if they are positive. The management of BSGs in adults remains non-standardized, largely because most glioma trials exclude tumors located in this specific site. To date, no prospective trials have established clear treatment guidelines, and most of the available data come from retrospective studies or extrapolation of data from other locations. Radiotherapy (RT) is one of the main treatment options for BSGs in adults. The role of chemotherapy remains unclear due to limited data in literature and is currently being studied. Several molecular targets with therapeutic potential, including recurrent genetic mutations and fusion transcripts, have been identified in adult BSGs.

The oncologist 2026 Oct 10 PubMed
03 Historical redlining and breast cancer screening in a regional spatial analysis. Asante D et al. 10.1093/jncics/pkag109
View abstract

BACKGROUND: Redlining, introduced in 1933 by the Homeowners' Loan Corporation, created enduring structural inequities in housing, health care access, and neighborhood investment. These historical patterns may contribute to persistent disparities in breast cancer screening. This study examines how historical redlining, alongside contemporary socioeconomic factors, shapes screening disparities across the University of Kansas Cancer Center (KUCC) catchment area. METHODS: We conducted a census tract-level spatial analysis across 123 counties (Kansas and western Missouri) by linking CDC PLACES breast cancer screening data with historical redlining maps. Explanatory variables included rurality, mammography facility availability, income inequality, gender pay gap, and uninsured rates. Logistic regression assessed overall associations, while geographically weighted binomial logistic regression evaluated spatial heterogeneity. RESULTS: Screening rates ranged from 56.9% to 84.5% across census tracts. Redlining was associated with lower screening odds in unadjusted models but was attenuated after accounting for socioeconomic and geographic factors. Rurality and income inequality were consistently associated with lower screening, whereas greater mammography facility availability was associated with higher screening rates. Spatial analyses revealed meaningful geographic variation, with localized negative associations of redlining and persistent, spatially varying effects of socioeconomic factors. CONCLUSION: Breast cancer screening disparities in this region reflect the combined influence of historical structural inequities and current socioeconomic conditions. Expanding access to mammography and implementing spatially targeted, equity-focused interventions may improve screening uptake and reduce disparities in underserved communities.

JNCI cancer spectrum 2026 Oct 10 PubMed
04 Circulating Tumor Cell Synaptophysin and Androgen Receptor Expression Reflect Prostate Cancer Phenotypes in Metastatic Disease. Lo E et al. 10.1002/pros.70267
View abstract

BACKGROUND: Chronic exposure to androgen receptor (AR)-targeted therapies can drive lineage plasticity, leading to treatment resistance and neuroendocrine prostate cancer (NEPC), characterized by loss of AR expression and acquisition of neuroendocrine (NE) markers including synaptophysin (SYP). We evaluated concordance between circulating tumor cell (CTC) AR and SYP expression patterns and evidence of NE differentiation defined by clinical, pathologic, and genomic features. METHODS: CTCs from patients with metastatic castration-resistant prostate cancer (mCRPC) were analyzed using the RareCyte platform with quantitative immunofluorescence imaging for SYP and AR. In patients with ≥ 5 CTCs, associations of CTC phenotype with PSA at collection and overall survival (OS) were assessed using the Wilcoxon rank-sum test, Fisher's exact test, and Kaplan-Meier analysis. Patients were retrospectively classified as AR-positive adenocarcinoma or NE-differentiated based on clinical, pathologic, and genomic data. RESULTS: The AR/SYP CTC assay was analytically validated using cell-line spike-in models, achieving > 90% accuracy for both biomarkers. Of 52 patients with mCRPC, 27 had ≥ 5 evaluable CTCs and were included in the primary CTC phenotype analyses. The NE-differentiated cohort had a higher fraction of SYP-positive CTCs (median 28.6% vs 0.0%, p = 0.0084), whereas the AR-positive adenocarcinoma cohort had a higher fraction of AR-positive CTCs (median 96.7% vs 0.0%, p = 0.0004). Classification based on high AR or SYP expression (≥ 80% of CTCs positive) significantly distinguished cohorts and was associated with tissue histology (p = 0.0048). PSA at CTC collection was lower in the NE-differentiated cohort (median 3.83 vs 486.89 ng/mL; 95% CI: -1016 to -190.9). OS did not significantly differ between groups. CONCLUSION: SYP and AR CTC expression showed strong concordance with tissue histology and clinical features of NE differentiation and AR-positive adenocarcinoma. These findings support the feasibility of CTC immunophenotyping to characterize lineage-associated phenotypes including SYP-expressing NE differentiation in mCRPC. Prospective validation in larger cohorts with matched tissue biopsies is needed to define the clinical utility of this approach.

The Prostate 2026 Oct 11 PubMed
05 Borrowing-dependent estimands in external-control trials: Identification, efficiency, and sensitivity in survival analysis. Bhattacharjee A et al. 10.1080/10543406.2026.2744763
View abstract

Augmenting randomised trials with external controls is increasingly common in oncology and rare diseases. This paper reviews the methodology of externally controlled trials - estimands, identification assumptions, estimation, efficiency and sensitivity analysis - for right-censored survival outcomes, and organises it around a single question: what quantity does a borrowing analysis actually deliver? We distinguish the estimand, fixed in advance by the clinical question and the target population, from the , the quantity to which a given borrowing rule is consistent. The two coincide under source-conditional exchangeability and separate otherwise, so that the borrowing-dependent estimand names, and makes estimable, a discrepancy that is otherwise reported only as unquantified bias. Within a nonparametric potential-outcomes framework we (i) define borrowing-weighted causal contrasts indexed by a weighting kernel and set out when such a contrast is, and is not, a scientifically meaningful target in its own right; (ii) establish nonparametric identification and derive the efficient influence function; (iii) construct a doubly robust, locally efficient estimator with -consistency; (iv) introduce a sensitivity-analysis framework yielding closed-form bias bounds, E-values, and tipping points; and (v) characterise the sensitivity of the delivered estimand to the pre-specified borrowing rule via Fréchet differentiability. Simulations across 12 factorial scenarios confirm up to 49% RMSE reduction under compatibility, show that the estimators remain unbiased for the borrowing-dependent estimand when compatibility fails, and validate the sensitivity bounds. A worked example in metastatic colorectal cancer illustrates the complete analytical workflow.

Journal of biopharmaceutical statistics 2026 Oct 11 PubMed
06 From Anatomy to Biology: Tumor Location has Limited Independent Value in Predicting Pathological Complete Response After Neoadjuvant Chemoradiotherapy. Akay O et al. 10.1177/00031348261497817
View abstract

BackgroundNeoadjuvant therapy is the standard treatment for locally advanced rectal cancer; however, treatment response remains heterogeneous, and research has increasingly shifted from isolated anatomical predictors toward biologically integrated response assessment. This study evaluated whether anatomical tumor location was independently associated with pathological response to neoadjuvant therapy.Materials and MethodsThis multicenter retrospective study included 179 patients with stages II-III rectal adenocarcinoma undergoing long-course neoadjuvant chemoradiotherapy followed by total mesorectal excision between January 2023 and January 2026. Tumor location was categorized as upper (>10 cm), mid (5-10 cm), or low (<5 cm) rectum. Pathological response was assessed using the modified Ryan system, and major response was defined as TRG 0-1. Multivariable binary logistic regression evaluated factors associated with major pathological response, with multinomial regression as a secondary exploratory analysis.ResultsIn the primary multivariable analysis, tumor location was not independently associated with major pathological response (global = .358). Major response occurred in 47.5% of patients without lymphovascular invasion but in only 3.3% of those with lymphovascular invasion, which was associated with lower odds of major response (OR 0.05, 95% CI 0.01-0.15; < .001).ConclusionAnatomical tumor location was not independently associated with pathological response following neoadjuvant chemoradiotherapy. These findings suggest that response assessment should extend beyond simple anatomical variables and be interpreted within the broader context of tumor biology and integrated clinicopathological assessment.

The American surgeon 2026 Oct 11 PubMed
07 Liquid Metal Multi-Functional Droplets Enabled High-Performance Tumor Therapy With Four Synergistic Mechano-Thermal-Chemo-Freezing Effects. Liu Y et al. 10.1002/smll.76152
View abstract

Cryoablation, which induces rapid intracellular ice crystal formation, has been widely used in clinics for treating various tumors, yet monotherapy yields limited efficacy due to inadequate elimination of tumor cells. Here, we proposed an effective synergistic strategy with intelligent biomaterials to overcome the limitation of conventional cryo-thermal therapy that requires two separate devices, integrating cryo-thermal ablation, mechanical destruction, and drug release to improve therapeutic efficacy. A sodium alginate (SA) modified iron-containing liquid metal microdroplet (FLMM@DOX@SA) was fabricated with diverse intelligent merits under stimulation. Under cooling, FLMM@SA would go through a multi-phase transition process and present a unique "bomb-explosion-like" behavior, leading to fierce mechanical destruction (more than 6.3 MPa) to surrounding ice crystals. Then, FLMM@SA was demonstrated as a powerful magnetocaloric agent when subject to an alternating magnetic field. In addition, this intelligent biomaterial exhibited stimulus-enhanced drug release across multiple cues, including cryo-stimulation, magnetothermal activation, and pH changes, thereby driving synergistic antitumor efficacy with the highest fraction of necrotic cells. The mechano-thermal-chemo-freezing synergistic therapy further verified the effective destructive performance with robust tumor growth suppression and a 100% animal survival rate. Collectively, this work highlights the integration of intelligent biomaterials into cryoablation, thereby forging a novel modality for highly effective combination therapy.

Small (Weinheim an der Bergstrasse, Germany) 2026 Oct 11 PubMed
08 D-- phenotype and anti-Rh17 alloimmunization: a comprehensive review of identification and clinical management. Shahverdi E et al. 10.2478/immunohematology-2026-017
View abstract

The D-- phenotype is an exceptionally rare Rh blood group phenotype characterized by expression of D in the complete absence of C, c, E, and e. Individuals with this phenotype are at risk of developing anti-Rh17 (anti-Hr), a clinically significant alloantibody that can severely complicate transfusion support and pregnancy management because compatible blood is exceptionally difficult to obtain. This review critically synthesizes the available published evidence regarding the D-- phenotype and anti-Rh17 alloimmunization, integrating data from case reports, case series, family investigations, and molecular studies from different geographic regions. Current evidence regarding molecular mechanisms, immunohematologic character istics, serologic identification, transf usion management, pregnancy outcomes, and rare donor strategies is summarized, w ith emphasis on practical considerations relevant to transfusion medicine. Although the D-- phenotype is exceptionally rare, early recognition, comprehensive immunohematologic evaluation, and proactive transfusion planning, including collaboration with rare donor programs, are essential for optimizing patient outcomes.

Immunohematology 2026 Sep 1 PubMed
09 Dynamic Covalent Prodrug Nanocomplex for Ultrasound-Triggered Oxidative Stress Amplification and Synergistic Sonochemotherapy. Jiang H et al. 10.1002/smll.76195
View abstract

Essential micronutrient Vitamin B (VB) is a bioactive compound with sonodynamic activity; however, it suffers from hydrophilic limitations. Herein, a dynamic prodrug nanocomplex (PTX-PBA/VB) was constructed via phenylboronic acid-diol interaction between VB and phenylboronic acid-functionalized paclitaxel prodrug (PTX-PBA). This reversible boronate ester linkage ensures colloidal stability while enabling external stimuli- or tumor microenvironment-triggered drug release. Under ultrasound irradiation, the nanocomplex generates singlet oxygen (O) and hydroxyl radical, inducing prodrug cleavage, on-demand paclitaxel release, glutathione depletion, and glutathione peroxidase 4 downregulation, leading to amplified oxidative stress and immunogenic cell death. Prolonged intratumoral retention (>7 days) was realized by loading PTX-PBA/VB nanocomplex into an injectable poly(amino acid) hydrogel. In vivo study presented remarkable tumor suppression in 4T1-bearing mice, attributed to enhanced intratumoral reactive oxygen species levels and lipid peroxidation accompanied by robust immune activation. This work establishes a promising dynamic covalent prodrug strategy for precise sonoimmunotherapy.

Small (Weinheim an der Bergstrasse, Germany) 2026 Oct 11 PubMed
10 TXNDC11 is associated with poor prognosis and promotes stress-associated survival in acute myeloid leukemia. Huang S et al. 10.1007/s13577-026-01460-7
View abstract

TXNDC11 is an endoplasmic reticulum-associated redox protein involved in protein quality control, but its relevance in acute myeloid leukemia remains incompletely understood. This study examined the expression pattern, prognostic value, and stress-related functional role of TXNDC11 in acute myeloid leukemia using public transcriptomic datasets and experimental validation. Bioinformatic analyses were used to evaluate TXNDC11 expression, survival association, protein interaction networks and pathway enrichment. Loss-of-function experiments were performed in acute myeloid leukemia cell lines to assess cell viability, oxidative stress status, endoplasmic reticulum stress signaling, and responses to the chemical chaperone 4-phenylbutyric acid. TXNDC11 expression was relatively elevated in acute myeloid leukemia samples and higher expression was associated with shorter overall survival. Protein interaction and enrichment analyses connected TXNDC11-associated networks with endoplasmic reticulum-associated degradation, unfolded protein response, endomembrane organization, and apoptosis-related pathways. In THP-1 and HL-60 cells, TXNDC11 knockdown reduced cellular viability and was accompanied by increased reactive oxygen species and malondialdehyde levels, decreased ATP content, reduced glutathione availability, and a lower GSH/GSSG ratio, indicating disruption of redox homeostasis. At the molecular level, TXNDC11 depletion increased GRP78/BiP, p-eIF2α/eIF2α, ATF4, p-IRE1α/IRE1α, cleaved ATF6 p50/full-length ATF6, DDIT3/CHOP mRNA, XBP1s mRNA, HSPA5/BiP mRNA, and cleaved caspase-3, supporting activation of multiple UPR-associated signals and apoptosis-associated marker expression. Treatment with 4-phenylbutyric acid partially attenuated these stress-related molecular and redox changes. Repeated local si-TXNDC11 administration suppressed AML xenograft growth and reduced TXNDC11 expression in endpoint tumor tissues. These findings suggest that TXNDC11 is linked to adverse prognosis in acute myeloid leukemia and may support leukemic cell stress adaptation by limiting endoplasmic reticulum stress-associated redox imbalance and apoptotic signaling.

Human cell 2026 Oct 11 PubMed
11 Necroptosis as a key player in cervical cancer progression and management: a systematic review and transcriptomic cross-study consensus analysis. Fobian SF et al. 10.1007/s10495-026-02440-w
View abstract

Immunotherapy has improved outcomes for a subset of patients with locally advanced cervical cancer. However, many tumors remain immunologically "cold" and fail to respond. Strategies that enhance tumor immunogenicity are therefore of increasing interest. Necroptosis, a regulated form of inflammatory cell death, has emerged as a potential mechanism capable of promoting the anti-tumor immune responses through the release of damage-associated molecular patterns and enhanced antigen presentation. In this study, we performed a systematic review and transcriptomic cross-study consensus analysis of all studies carried out describing the role and mechanisms of necroptosis occurrence in cervical cancers. We analyzed all published necroptosis-related prognostic gene signatures and integrated these findings into an exploratory transcriptomic analyses to identify mechanistic insights into interlinked biological pathways, and potential therapeutic targets. Following PRISMA guidelines, we analyzed seven published prognostic models, from studies using RNA sequencing and least absolute shrinkage and selection operator (LASSO)-based feature selection to generate a prognostic risk score for patients. We then conducted a comparative analyses of eight overlapping genes and their reported risk score coefficients. Across studies, seven necroptosis-related genes were identified, many of which are functionally linked to mitochondrial transport and permeability regulation, reactive oxygen species (ROS) generation, and inflammatory signaling. Overall, our findings support a key role for necroptosis in cervical cancer, where activation thereof is generally associated with enhanced immune infiltration and activation; thereby improved prognosis. These findings position necroptosis as a promising target for combination therapy strategies aimed at converting immunologically "cold" tumors into more responsive phenotypes. By integrating published signatures with exploratory analyses, we identify potential avenues to modulate necroptotic signaling in ways that may enhance synergy with immunotherapies, and have synthesized a hypothetical cell signaling and interaction diagram. Collectively, this work provides a foundation for future experimental validation and therapeutic development.

Apoptosis : an international journal on programmed cell death 2026 Oct 11 PubMed
12 Shedding light on the cancer cell death mechanism in photodynamic therapy. Moghassemi S et al. 10.1007/s10495-026-02458-0
View abstract

Photodynamic therapy (PDT) employs the interaction of a photosensitizer, light, and molecular oxygen to generate reactive oxygen species, which induce regulated cell death pathways that contribute to tumor eradication and immune modulation. Despite its clinical utility, the determinants of tumor selectivity remain incompletely understood. Current evidence suggests that PDT selectivity does not arise from a single mechanism but rather from the dynamic interplay among photosensitizer properties, tumor architecture, microenvironmental heterogeneity, and host immune responses. Here, we integrate current mechanistic understanding of PDT-induced cell death and discuss how tumor-specific factors, including enhanced permeability and retention, differential transporter expression, and microenvironmental heterogeneity, modulate photosensitizer accumulation. We further examine how photosensitizer subcellular localization, tumor biology, and immune microenvironment shape therapeutic outcomes. This integrated perspective highlights opportunities to guide the selection and optimization of PDT agents and treatment strategies toward improved selectivity and immunogenicity, while reinforcing PDT as a versatile modality within modern cancer therapy.

Apoptosis : an international journal on programmed cell death 2026 Oct 11 PubMed
13 Return of Mailed Multitarget Stool DNA Test Kits and Subsequent Colorectal Cancer Incidence in the United States: A Retrospective Cohort Study. Goyat R et al. 10.1007/s12325-026-03818-7
View abstract

INTRODUCTION: Completion of colorectal cancer (CRC) screening is essential to realizing the benefits of early detection and prevention; however, many individuals do not complete screening after a test is provided. The association between screening completion and subsequent CRC incidence remains poorly understood. We evaluated the association between multitarget stool DNA (mt-sDNA) test kit return and CRC incidence among average-risk adults. METHODS: This retrospective cohort study, linking claims data from Komodo Health with Abbott laboratory data, included adults aged 45-85 years who received an mt-sDNA kit between January 1, 2017, and December 31, 2019 (based on linked laboratory and claims data). The primary outcome was incident CRC identified using claims-based diagnosis codes. Propensity score-matched (PSM) and inverse probability treatment-weighted (IPTW) analyses assessed robustness to confounding. Adjusted incidence rate ratios (IRRs) were estimated using Poisson regression and hazard ratios (HRs) using Cox proportional hazards models. RESULTS: The cohort included 2,574,759 adults (60.5% female, 38.5% male; 68.2% White, 8.2% Black/African American, 6.5% Hispanic, 2.6% Asian/Pacific Islander, 14.4% other/unknown race), who contributed over 14 million person-years of follow-up. CRC incidence was lower among kit returners than non-returners (248.95 vs 301.89 per 100,000 person-years). In adjusted analyses, mt-sDNA kit return was associated with 55% lower CRC incidence versus non-return [IRR 0.45; 95% confidence interval (CI) 0.45-0.46; p < 0.0001], with similar findings in PSM (IRR 0.58; 95% CI 0.57-0.59) and IPTW analyses (IRR 0.28; 95% CI 0.28-0.28). Supportive time-to-event analyses demonstrated directionally consistent associations, with mt-sDNA kit return associated with improved CRC-free survival (HR 0.76; 95% CI 0.74-0.78; p < 0.0001). CONCLUSIONS: In this large retrospective cohort study, mt-sDNA screening completion was consistently associated with lower CRC incidence across unmatched, PSM, and IPTW analyses. These findings support strategies to improve stool-based CRC screening completion to maximize the population-level benefits of CRC screening programs.

Advances in therapy 2026 Oct 11 PubMed
14 Nano-engineered phytochemicals in cancer therapy: mechanistic insights into apoptosis, ferroptosis, tumor microenvironment modulation and drug resistance reversal. Sahu P et al. 10.1007/s10495-026-02452-6
View abstract

Cancer progression and therapeutic resistance are driven by interconnected mechanisms involving redox imbalance, metabolic plasticity, epigenetic remodeling and tumor microenvironment (TME)-mediated immune suppression. Conventional "one drug-one target" therapies often fail to overcome these adaptive oncogenic networks, resulting in multidrug resistance and disease relapse. This review aims to explore the therapeutic potential of nano-engineered phytochemicals in cancer management, with emphasis on ferroptosis induction, oncogenic pathway modulation and TME reprogramming for overcoming tumor resistance. A comprehensive narrative review was conducted focusing on recent advances in nano-phytomedicine, ferroptosis-based anticancer strategies and precision nanotherapeutic approaches. Relevant literature was systematically collected from PubMed, Scopus, ScienceDirect and Web of Science databases, considering both preclinical and clinical studies. Retrieved studies were critically analyzed to evaluate the therapeutic effects of nano-engineered phytochemicals on major oncogenic signaling pathways, including PI3K/Akt, NF-κB, STAT3, HIF-1α and NRF2. Mechanistic evidence associated with ferroptosis induction, reactive oxygen species (ROS) modulation, oxidative stress regulation, immune reprogramming and tumor microenvironment (TME) remodeling was systematically assessed. Preclinical studies indicate that nano-engineered phytochemicals can modulate interconnected oncogenic, metabolic, redox and immune pathways and can improve physicochemical and pharmacokinetic properties relative to free phytochemicals. Ferroptosis-associated effects include modulation of glutathione metabolism, GPX4, SLC7A11, iron homeostasis and lipid peroxidation; however, these molecular changes do not independently establish ferroptotic cell death. Evidence for tumour-microenvironment modulation and multidrug-resistance reversal remains predominantly preclinical, whereas human studies are limited and mainly address pharmacokinetic, tolerability or early efficacy outcomes. Nano-engineered phytochemicals represent a promising systems-oriented therapeutic strategy, but their clinical potential remains incompletely established. Future development requires rigorous mechanistic validation, reproducible formulation and manufacturing processes, biomarker-guided clinical evaluation, and comprehensive assessment of biodistribution, toxicity and long-term safety. Clinical trial: The manuscript is a review article (not a part of Clinical trial), hence no Clinical trial no is applicable.

Apoptosis : an international journal on programmed cell death 2026 Oct 11 PubMed
15 Baseline circulating immunophenotype as a predictor of immune-related adverse events in NSCLC patients treated with immune checkpoint inhibitors. Dodi A et al. 10.1080/1750743X.2026.2738332
View abstract

BACKGROUND: Immune-related adverse events (irAEs) represent a challenge in non-small cell lung cancer (NSCLC) patients receiving immune checkpoint inhibitors (IO). Baseline circulating immunophenotype may identify patients at increased irAEs risk. METHODS: This observational study included patients with advanced NSCLC receiving IO alone or with chemotherapy. Baseline clinicopathological data and blood samples were prospectively analyzed to investigate the association of clinicopathological characteristics, circulating immune cells and cytokines, with irAEs onset, severity, timing, and type. RESULTS: 178 patients were included; 52.2% ( = 93) developed irAEs, more frequently involving those with good ECOG PS, first-line treatment, favorable LIPI, higher albumin. These patients showed higher baseline lymphomonocytes and lower CD4CD25Foxp3 T cells ( = 0.05 and 0.04, respectively). Logistic regression confirmed lymphocyte enrichment as independently associated and Tregs as protective ( = 0.05 for both). High-grade and early-onset irAEs were associated with increased PD-1+ T and NK cells, cytotoxic/proliferative T-cell markers, and reduced inhibitory signals (i.e. sPD-L1). Distinctive immune profiles outlined gastrointestinal and cutaneous toxicities. CONCLUSIONS: Baseline circulating immunophenotype showed exploratory association with irAE risk, severity, timing, and pattern in this setting. No association retained statistical significance after false discovery rate (FDR) adjustment. These findings should be considered hypothesis-generating and require independent external validation.

Immunotherapy 2026 Oct 11 PubMed
16 Pharmacogenomics of cancer therapy-related cardiomyopathy in childhood cancer survivors. Poudel S et al. 10.1080/14622416.2026.2732153
View abstract

Cancer therapy-related cardiomyopathy (CTR-cardiomyopathy) is the leading noncancer late effect contributing to morbidity and mortality among adult survivors of childhood cancer. Anthracycline chemotherapy and thoracic radiotherapy are the primary treatment-related risk factors. However, substantial variability among similarly treated individuals highlights the role of germline genetic susceptibility. This review summarizes pharmacogenomic evidence for CTR-cardiomyopathy and the integration of genetic and clinical risk factors for individualized risk prediction. We searched PubMed through July 2026 for studies examining the molecular underpinnings and risk prediction in these survivors. Candidate gene studies identified associations across pathways involved in drug transport (, , ), metabolism (), oxidative stress (, , ), DNA damage response (, , ), and inflammation (7). Genome-wide studies have identified additional loci, including HAS3, ancestry-specific signals (, ), and a doxorubicin-specific locus (). Despite progress, barriers to clinical implementation remain, including heterogeneous phenotype definitions, limited replication, especially in non-European populations, and lack of prospectively validated risk models. Integration of multi-omics approaches may improve detection of subclinical cardiac injury. Ultimately, combining polygenic and other omic risk scores with clinical factors and validating these models prospectively across diverse populations will be essential for advancing precision survivorship care.

Pharmacogenomics 2026 Oct 11 PubMed
17 Evaluating early systemic therapies in the neoadjuvant setting for the treatment of urological cancers. Stamatakos PV et al. 10.1080/13543784.2026.2748359
View abstract

INTRODUCTION: Neoadjuvant systemic therapy represents an evolving cornerstone in the multidisciplinary management of urological malignancies. While cisplatin-based neoadjuvant chemotherapy historically represented the sole standard of care for muscle-invasive bladder cancer, novel perioperative regimens - combining preoperative induction with adjuvant maintenance - have established chemotherapy as only a standard of care alongside emerging antibody-drug conjugate and immunotherapy combinations. In renal cell carcinoma and prostate cancer, preoperative approaches remain largely investigational. AREAS COVERED: A structured search of PubMed/MEDLINE, Embase, and ClinicalTrials.gov was conducted up to August 2026. This review critically appraises prospective Phase I and II investigational trials evaluating novel systemic therapies across renal cell carcinoma, upper tract urothelial carcinoma, muscle-invasive bladder cancer, and prostate cancer, contextualizing pivotal Phase III benchmarks. EXPERT OPINION: Neoadjuvant and perioperative paradigms are shifting toward personalized, biomarker-driven strategies. Key challenges include determining the independent necessity of postoperative maintenance in pathological complete responders, establishing validated surrogate endpoints in renal cell carcinoma and prostate cancer, and overcoming significant socioeconomic and geographic access disparities. Incorporating circulating tumor DNA kinetics and predictive biomarkers will be pivotal for optimizing patient selection and guiding response-adaptive therapy.

Expert opinion on investigational drugs 2026 Oct 11 PubMed
18 Clinical and genetic risk factors for apolipoprotein L1-mediated chronic kidney disease in people of African ancestry with HIV. Post FA et al. 10.1097/QCO.0000000000001253
View abstract

PURPOSE OF REVIEW: To summarize current understanding of the epidemiology, pathogenesis and management of HIV-Associated Nephropathy (HIVAN) and other forms of Apolipoprotein L1 (APOL1)-mediated chronic kidney disease (CKD) in people of African ancestry with HIV. RECENT FINDINGS: The G1 and G2 variants of the APOL1 gene, which have emerged in trypanosomiasis-endemic areas of Africa, predispose to HIV-associated nephropathy (HIVAN) and other forms of CKD. The risk of APOL1-mediated CKD is attenuated with HIV control and carriage of the p.N264K genetic variant. Several treatments targeting the APOL1 gene and the transmembrane ion channel encoded by the APOL1 gene are being evaluated in clinical trials; early findings indicate they achieve rapid and marked reductions in proteinuria in those with established APOL1-mediated CKD. SUMMARY: Genetic variants of APOL1 are causally implicated in HIVAN and other forms of severe CKD in populations of African ancestry with HIV. Genetic, epigenetic and environmental factors influence the risk of developing APOL1-mediated CKD, and emerging APOL1-directed therapies offer the prospect of clinical remission to those with established APOL1-mediated CKD.

Current opinion in infectious diseases 2026 Oct 12 PubMed
19 Deceased donor interposition graft repair of superior mesenteric artery injury during cytoreductive nephrectomy for metastatic renal cell carcinoma. Iranpour N et al. 10.1093/jscr/rjag876
View abstract

Iatrogenic injury to the superior mesenteric artery (SMA) represents a rare but serious complication of nephrectomy, associated with significant morbidity and mortality. Repair can be technically challenging. We describe the case of a 71-year-old patient who had an SMA injury during an open nephrectomy for a large carcinoma. Her SMA was reconstructed successfully using a deceased-donor iliac artery interposition graft. Due to her high-risk pathology and progressive disease early in the post-operative period, she was commenced on lenvatinib and pembrolizumab. Despite the vascular allograft, immunosuppression was not used due to concerns about an interaction with immunotherapy. To date, she has had an excellent treatment response with a significant reduction in metastatic burden without the development of rejection of the vascular allograft, despite no immunosuppression.

Journal of surgical case reports 2026 Oct PubMed
20 Prediction of prognosis and treatment effect of cervical cancer by immunogenic cell death-related genes. Li X et al. 10.7717/peerj.21635
View abstract

BACKGROUND: Immunogenic cell death (ICD) is a potential mechanism that mediates adaptive immune responses during anticancer therapy. However, expression patterns and clinical implications of ICD related genes in cervical squamous cell carcinoma and endocervical adenocarcinoma (CESC) remain unclear. This study aimed to investigate the associations of 34 ICD related genes with immune characteristics, prognosis, and immune checkpoint blocking (ICB) efficacy in CESC and to predict drug responses across different risk subgroups. METHODS: Ribonucleic acid sequencing (RNA-seq) transcriptomic profiles, standard normalized variate (SNV) data, and corresponding clinicopathological information were retrieved from The Cancer Genome Atlas (TCGA). Consensus clustering was applied to identify two ICD related molecular subtypes. A prognostic signature was constructed using least absolute shrinkage and selection operator (LASSO) Cox regression and validated using immunohistochemistry (IHC) and receiver operating characteristic (ROC) curve analyses. Immunotherapy responses were predicted based on the risk score of the established model. RESULTS: The ICD-high subtype (C2) was associated with favorable clinical outcomes and enhanced immune activation. The prognostic signature comprised six genes: ATG5, FOXP3, IFNG, IL1B, PDIA3, and TNF. IHC confirmed higher expression of ATG5 and PDIA3 in cervical cancer (CC) tissues than in normal cervical tissues, and ROC curves verified the predictive accuracy. Furthermore, immunophenoscore (IPS) and tumor immune dysfunction and exclusion (TIDE) scores suggested that low risk patients exhibited better responses to anti programmed cell death protein-1 (PD-1) immunotherapy. CONCLUSIONS: This study characterized the expression profiles of ICD related genes and established a novel ICD based classification system for CESC. Comprehensive analyses of the tumor immune microenvironment further validated the capacity of this signature in predicting prognosis and immunotherapy benefits, which may help identify CC patients who are most likely to benefit from immunotherapy.

PeerJ 2026 PubMed
21 Neonatal airway emergency: congenital laryngeal myxoma. Alqahtani HK et al. 10.1093/jscr/rjag904
View abstract

Laryngeal myxomas are exceptionally rare benign mesenchymal tumors, particularly in the pediatric population. We present a case of a neonate with a history of brief endotracheal intubation who developed inspiratory stridor and respiratory distress. Flexible laryngoscopy revealed a pedunculated mass on the right true vocal cord. The lesion was completely excised via microlaryngobronchoscopy. Definitive histopathological and immunohistochemical analysis-showing a hypocellular myxoid stroma, bland spindle cells, a low Ki-67 proliferation index (<5%), and positivity for CD34 with negative staining for S-100, desmin, smooth muscle actin, myogenin, ALK1, and -catenin-confirmed the diagnosis of a congenital laryngeal myxoma, differentiating it from a reactive post-intubation granuloma. This case highlights the importance of definitive histopathological diagnosis over presumptive clinical history and emphasizes the inclusion of rare congenital neoplasms in the differential diagnosis of neonatal stridor. Complete surgical excision is the treatment of choice.

Journal of surgical case reports 2026 Oct PubMed
22 Somatic Mutation-Informed Transcriptional Architecture of Hepatocellular Carcinoma: A Multiomics Study Centered on TP53. Zhang S et al. 10.1155/humu/2377057
View abstract

Hepatocellular carcinoma (HCC) is characterized by extensive somatic mutation heterogeneity, yet the cellular contexts in which recurrent driver mutation-associated transcriptional programs operate remain incompletely defined. In this study, we applied a mutation-informed multiomics framework centered on to connect somatic mutation status, bulk transcriptional programs, and hepatocyte-like cell states at single-cell resolution. Somatic mutation profiles and transcriptomic data from the TCGA-LIHC cohort were used to construct directional mutation-associated transcriptional signatures, with retained as a reference driver signature and and retained for descriptive comparison. These bulk-derived transcriptional programs were then projected into single-cell RNA sequencing data to evaluate inferred -associated transcriptional activity across hepatocyte-like populations. mutation-associated transcriptional programs were enriched in proliferation-related pathways, DNA repair processes, and stress-response programs and were associated with adverse clinical outcomes. At the single-cell level, inferred -associated transcriptional activity showed heterogeneous distribution across hepatocyte-like populations and was preferentially enriched in putative malignant hepatocyte-like states. Pseudobulk and functional program analyses further supported the association between -high signature states, cell-cycle activity, DNA repair, stress programs, and altered tumor-cell communication patterns. Integrated prioritization identified , , and as representative genes associated with -related transcriptional programs; these genes should be interpreted as components of a -associated proliferative transcriptional state rather than as experimentally validated drivers. These findings provide a mutation-informed view of transcriptional architecture in HCC and illustrate how bulk mutation-associated signatures can be integrated with single-cell data to improve biological interpretation of somatic variation.

Human mutation 2026 PubMed
23 Not Whether, but in Whom: Reframing Antibody-Drug Conjugate Sequencing in Metastatic Breast Cancer. Orlandi A 10.1002/cai2.70085 Cancer innovation 2026 Oct PubMed
24 Proximal Tracheal Mucoepidermoid Carcinoma Complicated by Early Anastomotic Stenosis-A Case Report. Pandya S et al. 10.1002/ccr3.73721
View abstract

Proximal tracheal mucoepidermoid carcinoma may remain occult despite prolonged upper-airway symptoms and normal flexible nasoendoscopy. Stridor following tracheal resection should prompt assessment of the anastomosis, as early postoperative stenosis caused by A-frame deformity and granulation tissue may be successfully managed with combined laser therapy, balloon dilatation, and intralesional corticosteroid injection.

Clinical case reports 2026 Oct PubMed
25 Immune-Complex-Based In Vitro Deubiquitination Assay. Dô F et al. 10.21769/BioProtoc.5824
View abstract

Deubiquitinases (DUBs) are attractive therapeutic targets within the ubiquitin-proteasome system, in part because four of the five DUB subfamilies are cysteine proteases amenable to the development of potent, selective inhibitors, as recently demonstrated for USP7. Identifying DUBs that deubiquitylate and stabilize specific human oncogenic proteins is therefore a promising approach to discovering new mechanism-based targets for cancer therapy. Several complementary experimental strategies are typically required to identify bona fide DUB-substrate pairs. Here, we present an efficient, straightforward in vitro immune-complex protocol to validate USP17-mediated deubiquitylation of the transcriptional co-activator β-catenin. In this assay, both β-catenin and USP17 are immunopurified from transiently transfected 293T cells and then combined to assess USP17 enzymatic activity. The protocol describes the in vitro enzymatic assay performed on immunopurified complexes and the immunoblot-based readout. It can be readily adapted to other DUBs and substrates for mechanistic studies. Key features • Requires prior experience with cell culture, immunoprecipitation, and immunoblot analysis. • Uses plasmids encoding epitope-tagged DUB (here, USP17), the substrate of the DUB of interest (here, β-catenin), and ubiquitin, which are transiently expressed in 293T cells. • Expression in mammalian cells preserves DUB (here, USP17) essential post-translational modifications. • Adaptable to other DUB-substrate pairs.

Bio-protocol 2026 Oct 5 PubMed
DoctiPlus Health Insights are compiled weekly from public trial registries, FDA databases, and academic publishers. All figures reflect the seven-day window ending on the report date. Data is provisional and subject to registry updates.

Primary sources

  • ClinicalTrials.gov — public registry
  • openFDA — adverse events & recalls
  • PubMed / NCBI — research papers
  • Semantic Scholar — citations & papers

About this report

  • Category: Cancer & Oncology
  • Week: October 5 – October 12, 2026
  • Drugs tracked: New Trials This Week, Recruiting Now, Countries
  • Generated: November 16, 2026 at 7:26 AM
© 2026 DoctiPlus Care Vol. 7 · No. 47 · November 16, 2026 — 30 —